NasdaqCM - Nasdaq Real Time Price USD

Unicycive Therapeutics, Inc. (UNCY)

Compare
0.7000 -0.0145 (-2.03%)
At close: December 16 at 4:00:00 PM EST
0.7099 +0.01 (+1.41%)
After hours: 7:54:29 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for UNCY

Recent News: UNCY

View More
Breakeven On The Horizon For Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Breakeven On The Horizon For Unicycive Therapeutics, Inc. (NASDAQ:UNCY)
Simply Wall St. 18 days ago
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference

Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire 25 days ago
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire last month
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
GlobeNewswire last month
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024

Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
GlobeNewswire last month
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024

Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
GlobeNewswire last month
Results of Phase I trial shed positive light on UNI-494 for acute kidney injury

Results of Phase I trial shed positive light on UNI-494 for acute kidney injury
Clinical Trials Arena last month
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024

Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024
GlobeNewswire 2 months ago
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers

Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
GlobeNewswire 2 months ago
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024
GlobeNewswire 2 months ago
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
GlobeNewswire 2 months ago
View More

Related Tickers

ELEV Elevation Oncology, Inc.
0.6400
+0.61%
 
ARDX Ardelyx, Inc.
5.39
+3.26%
 
XFOR X4 Pharmaceuticals, Inc.
0.6450
-3.76%
 
MIST Milestone Pharmaceuticals Inc.
1.7900
-0.56%
 
CGTX Cognition Therapeutics, Inc.
0.4510
-5.65%
 
EYEN Eyenovia, Inc.
0.0816
-2.28%
 
ENSC Ensysce Biosciences, Inc.
6.41
+14.06%
 
GOSS Gossamer Bio, Inc.
0.8578
-7.76%
 
GRCE Grace Therapeutics, Inc.
3.6400
+1.68%
 
SPRB Spruce Biosciences, Inc.
0.3887
+1.44%